UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware	 	32-0546926	
(State of incorporation or organization)	 	(I.R.S. Employer Identification No.)	

 
	
Amneal Pharmaceuticals, Inc.
c/o Impax Laboratories, Inc.
30831 Huntwood Ave.
Hayward, CA 94544
(510) 240-6000	
(Address of principal executive offices and zip code)	
Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class
to be so registered	 	Name of each exchange on which
each class is to be registered	
		
Class A Common Stock	 	New York Stock Exchange	
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box   ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box   ☐
Securities Act registration statement file number to which this form relates: 333-221707
Securities to be registered pursuant to Section 12(g) of the Act: None

 

Item 1. Description of Registrant’s Securities to be Registered.
A description of the Class A Common Stock, par value $0.01 per share, of Amneal Pharmaceuticals, Inc. (the “Registrant”) is set forth under the caption “New Amneal Capital Stock” in the prospectus included in the Registrant’s Registration Statement on Form S-4 (Registration No. 333-221707), initially filed with the Securities and Exchange Commission (the “Commission”) on November 21, 2017 under the Securities Act of 1933, as amended, and will be set forth in any prospectus filed in accordance with Rule 424(b) thereunder, which description is incorporated herein by reference.
Item 2. Exhibits.
None. Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on the New York Stock Exchange and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

	 		 	Amneal Pharmaceuticals, Inc.	
				
Date: May 4, 2018	 		 	By:	 	/s/ Bryan M. Reasons	
	 		 		 	Bryan M. Reasons	
	 		 		 	Chief Financial Officer